Aims: Determine association between insomnia and risk of type 2 diabetes (T2DM).
Methods: We conducted a retrospective panel cohort study to examine risk of developing T2DM among prediabetes patients with and without insomnia (physician identified or insomnia medication dispense). Participants with prediabetes (physician identified or by 2 laboratory tests) between 1/1/2007 and 12/31/2015 were followed until 12/31/2016. Patients were determined to have T2DM when two of the following occurred within 2 years: physician-entered outpatient T2DM diagnosis, dispensing of an anti-hyperglycemia agent, A1C ≥6.5%, or fasting plasma glucose >125 mg/dl. One hospital inpatient stay with an associated T2DM diagnosis was also sufficient for T2DM classification.
Results: Our cohort comprised 79,608 persons with prediabetes. Almost 30% (23,370) were classified as having insomnia during the observation period. After adjustment for traditional risk factors, those with insomnia were 28% more likely to develop T2DM than those without. This estimate was essentially unchanged after adjusting for baseline A1C level (Table).
E. LeBlanc: None. N. Smith: None. M. Allison: None. G. Nichols: Research Support; Self; Boehringer Ingelheim GmbH, Amarin Corporation, Janssen Pharmaceuticals, Inc., Sanofi. G. Clarke: None.